Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXsT. P. Reddy(Texas A&M Health Science Center), Roberto R. Rosato(Methodist Hospital)Breast Cancer ResearchMay 15, 202010.1186/s13058-020-01280-zCited by 14SaveCiteExport RISWatch citationsRelated PapersEvaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models|Breast Cancer Research|2018|112